Literature DB >> 25828948

MCF-7 cells--changing the course of breast cancer research and care for 45 years.

Adrian V Lee1, Steffi Oesterreich1, Nancy E Davidson2.   

Abstract

It is 45 years since a pleural effusion from a patient with metastatic breast cancer led to the generation of the MCF-7 breast cancer cell line. MCF-7 is the most studied human breast cancer cell line in the world, and results from this cell line have had a fundamental impact upon breast cancer research and patient outcomes. But of the authors for the nearly 25000 scientific publications that used this cell line, how many know the unique story of its isolation and development? In this commentary we will review the past, present, and future of research using MCF-7 breast cancer cells.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25828948     DOI: 10.1093/jnci/djv073

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  56 in total

1.  MCF-7 as a Model for Functional Analysis of Breast Cancer Risk Variants.

Authors:  Alix Booms; Gerhard A Coetzee; Steven E Pierce
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-07-10       Impact factor: 4.254

2.  The transcriptomic response of cells to a drug combination is more than the sum of the responses to the monotherapies.

Authors:  Jennifer El Diaz; Mehmet Eren Ahsen; Thomas Schaffter; Xintong Chen; Ronald B Realubit; Charles Karan; Andrea Califano; Bojan Losic; Gustavo Stolovitzky
Journal:  Elife       Date:  2020-09-18       Impact factor: 8.140

3.  Tumor cells endowed with professional antigen-presenting cell functions prime PBLs to generate antitumor CTLs.

Authors:  Chiara Chiozzini; Eleonora Olivetta; Massimo Sanchez; Claudia Arenaccio; Flavia Ferrantelli; Patrizia Leone; Maurizio Federico
Journal:  J Mol Med (Berl)       Date:  2019-06-03       Impact factor: 4.599

4.  The cholesterol metabolite 27-hydroxycholesterol regulates p53 activity and increases cell proliferation via MDM2 in breast cancer cells.

Authors:  Shaneabbas Raza; Joyce E Ohm; Archana Dhasarathy; Jared Schommer; Conor Roche; Kimberly D P Hammer; Othman Ghribi
Journal:  Mol Cell Biochem       Date:  2015-09-08       Impact factor: 3.396

Review 5.  Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance.

Authors:  John A Katzenellenbogen; Christopher G Mayne; Benita S Katzenellenbogen; Geoffrey L Greene; Sarat Chandarlapaty
Journal:  Nat Rev Cancer       Date:  2018-06       Impact factor: 60.716

6.  Breast cancer cell obatoclax response characterization using passivated-electrode insulator-based dielectrophoresis.

Authors:  Sepeedah Soltanian-Zadeh; Kruthika Kikkeri; Ayesha N Shajahan-Haq; Jeannine Strobl; Robert Clarke; Masoud Agah
Journal:  Electrophoresis       Date:  2017-07-05       Impact factor: 3.535

Review 7.  Epigenetic polypharmacology: A new frontier for epi-drug discovery.

Authors:  Daniela Tomaselli; Alessia Lucidi; Dante Rotili; Antonello Mai
Journal:  Med Res Rev       Date:  2019-06-20       Impact factor: 12.944

8.  Acquired Tamoxifen Resistance in MCF-7 Breast Cancer Cells Requires Hyperactivation of eIF4F-Mediated Translation.

Authors:  Dedra H Fagan; Lynsey M Fettig; Svetlana Avdulov; Heather Beckwith; Mark S Peterson; Yen-Yi Ho; Fan Wang; Vitaly A Polunovsky; Douglas Yee
Journal:  Horm Cancer       Date:  2017-06-02       Impact factor: 3.869

9.  Machine Learning with Optical Phase Signatures for Phenotypic Profiling of Cell Lines.

Authors:  Van K Lam; Thanh Nguyen; Thuc Phan; Byung-Min Chung; George Nehmetallah; Christopher B Raub
Journal:  Cytometry A       Date:  2019-04-22       Impact factor: 4.355

10.  Modeling Neoadjuvant chemotherapy resistance in vitro increased NRP-1 and HER2 expression and converted MCF7 breast cancer subtype.

Authors:  Noura Al-Zeheimi; Sirin A Adham
Journal:  Br J Pharmacol       Date:  2020-02-15       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.